RemeGen’s Telitacicept Approved for Myasthenia Gravis in China
China-based pharmaceutical firm RemeGen (HKG: 9995) announced the third indication approval from the National Medical...
Biogen and City Therapeutics Collaborate on RNAi Therapies for CNS Diseases
US-based Biogen Inc. (NASDAQ: BIIB) announced a strategic collaboration with compatriot firm City Therapeutics, Inc....
HKSH Medical Partners with United Imaging to Advance CT Technology
Hong Kong-based private healthcare provider HKSH Medical Group announced the signing of a Memorandum of...
AstraZeneca’s Imfinzi Gets Positive Opinion for Bladder Cancer Perioperative Treatment
UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) announced that the European Medicines Agency’s (EMA) Committee...
EyePoint’s Partner Betta Completes Enrollment for Duravyu’s Pivotal Phase III Study
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), the US partner of China-based Betta Pharmaceuticals (SHE: 300558), announced...
EMA Recommends Tevimbra for Nasopharyngeal Cancer First-line Treatment
The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended...
AbelZeta Pharma’s C-CAR168 Secures FDA RMAT Designation for Lupus Treatments
Sino-US biotech AbelZeta Pharma, Inc., based in Rockville, Maryland, and with operations in Shanghai, announced...
FDA Rejects Data from Two Chinese Testing Labs Over Compliance Concerns
The U.S. Food and Drug Administration (FDA) late last week issued General Correspondence Letters to...
CARsgen’s Satricabtagene Autoleucel Granted Priority Review by China’s CDE
China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced that the Center for Drug Evaluation...
Salubris Pharma’s Xinchaotuo Gains NMPA Approval for Primary Hypertension
China-based Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) announced that it has received marketing approval...
Jiangsu Nhwa’s Investee Jiangsu Haoxinqing Plans Overseas Listing
China-based Jiangsu Nhwa Pharmaceutical Co., Ltd (SHE: 002262) announced that its investee company Jiangsu Haoxinqing...
Shenyang Xingqi Pharmaceuticals Plans Private Placement to Fund R&D Center
China-based Shenyang Xingqi Pharmaceutical Co., Ltd (SHE: 300573) announced plans for a private placement of...
Novartis’ Beovu Approved by NMPA for Diabetic Macular Edema Treatment
Swiss giant Novartis’ (NYSE: NVS) Beovu (brolucizumab) received approval from China’s National Medical Products Administration...
Mabworks’ MIL62 Gains NMPA Review for NMOSD Treatment
China-based Beijing Mabworks Biotech Co., Ltd announced that its New Drug Application (NDA) for MIL62,...
EpimAb Biotherapeutics and Juri Biosciences Ink Global Licensing Deal for KLK2-CD3 T-Cell Engager
Shanghai-based biotech EpimAb Biotherapeutics announced a global licensing agreement with US-headquartered Juri Biosciences, Inc., a...
Eli Lilly to Acquire SiteOne Therapeutics for Up to USD 1 Billion
US-based pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) announced plans to acquire compatriot biotech...
Junshi Biosciences’ Junshida Wins NMPA Approval for HeFH and Statin-Intolerant Patients
China’s Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) announced that it has received...
Sino Biopharmaceutical Presents TQB2102 Phase I Results at ASCO 2025
China-based Sino Biopharmaceutical Ltd (HKG: 1177) presented preliminary results from a Phase I clinical study...
BeiGene Rebrands to BeOne Medicines and Relocates to Switzerland
BeiGene (NASDAQ: ONC, HKG: 6160, SHA: 688235), a global oncology company, has officially rebranded to...
Betta Pharmaceuticals Partners with BioRay for Herceptin Biosimilar Anruize
China-based Betta Pharmaceuticals (SHE: 300558) announced a strategic partnership with fellow domestic firm BioRay Biopharmaceutical....